{
    "zip": "4811 AH",
    "sector": "Healthcare",
    "fullTimeEmployees": 336,
    "longBusinessSummary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
    "city": "Breda",
    "phone": "31 763 030 488",
    "country": "Netherlands",
    "companyOfficers": [],
    "website": "https://www.argenx.com",
    "maxAge": 1,
    "address1": "Willemstraat 5",
    "industry": "Biotechnology",
    "ebitdaMargins": -0.53524,
    "profitMargins": -0.73046994,
    "grossMargins": -0.00802,
    "operatingCashflow": null,
    "revenueGrowth": -0.465,
    "operatingMargins": -0.53761,
    "ebitda": -273016608,
    "targetLowPrice": 300,
    "recommendationKey": "buy",
    "grossProfits": -270945000,
    "freeCashflow": null,
    "targetMedianPrice": 366,
    "currentPrice": 312.58,
    "earningsGrowth": null,
    "currentRatio": null,
    "returnOnAssets": null,
    "numberOfAnalystOpinions": 18,
    "targetMeanPrice": 376.22,
    "debtToEquity": 0.267,
    "returnOnEquity": null,
    "targetHighPrice": 455,
    "totalCash": 2730996992,
    "totalDebt": 7881000,
    "totalRevenue": 510079840,
    "totalCashPerShare": 53.134,
    "financialCurrency": "USD",
    "revenuePerShare": 9.913,
    "quickRatio": null,
    "recommendationMean": 1.8,
    "exchange": "NMS",
    "shortName": "argenx SE",
    "longName": "argenx SE",
    "exchangeTimezoneName": "America/New_York",
    "exchangeTimezoneShortName": "EST",
    "isEsgPopulated": false,
    "gmtOffSetMilliseconds": "-18000000",
    "underlyingSymbol": null,
    "quoteType": "EQUITY",
    "symbol": "ARGX",
    "underlyingExchangeSymbol": null,
    "headSymbol": null,
    "messageBoardId": "finmb_62120637",
    "uuid": "96295c13-e973-32ba-ba5e-28b94bffe0bd",
    "market": "us_market",
    "annualHoldingsTurnover": null,
    "enterpriseToRevenue": 28.677,
    "beta3Year": null,
    "enterpriseToEbitda": -53.577,
    "52WeekChange": null,
    "morningStarRiskRating": null,
    "forwardEps": -19.13,
    "revenueQuarterlyGrowth": null,
    "sharesOutstanding": 51515000,
    "fundInceptionDate": null,
    "annualReportExpenseRatio": null,
    "totalAssets": null,
    "bookValue": 57.432,
    "sharesShort": 1392021,
    "sharesPercentSharesOut": 0.027,
    "fundFamily": null,
    "lastFiscalYearEnd": 1609372800,
    "heldPercentInstitutions": 0.55743,
    "netIncomeToCommon": -372597760,
    "trailingEps": -7.241,
    "lastDividendValue": null,
    "SandP52WeekChange": null,
    "priceToBook": 5.4426103,
    "heldPercentInsiders": 0,
    "nextFiscalYearEnd": 1672444800,
    "yield": null,
    "mostRecentQuarter": 1632960000,
    "shortRatio": 6.17,
    "sharesShortPreviousMonthDate": 1636934400,
    "floatShares": 46676668,
    "beta": 0.798007,
    "enterpriseValue": 14627530752,
    "priceHint": 2,
    "threeYearAverageReturn": null,
    "lastSplitDate": null,
    "lastSplitFactor": null,
    "legalType": null,
    "morningStarOverallRating": null,
    "earningsQuarterlyGrowth": null,
    "priceToSalesTrailing12Months": 31.940613,
    "dateShortInterest": 1639526400,
    "pegRatio": -1.17,
    "ytdReturn": null,
    "forwardPE": -16.33978,
    "lastCapGain": null,
    "shortPercentOfFloat": null,
    "sharesShortPriorMonth": 1002886,
    "category": null,
    "fiveYearAverageReturn": null,
    "previousClose": 332.67,
    "regularMarketOpen": 326.36,
    "twoHundredDayAverage": 302.21136,
    "trailingAnnualDividendYield": null,
    "payoutRatio": 0,
    "volume24Hr": null,
    "regularMarketDayHigh": 328.71,
    "navPrice": null,
    "averageDailyVolume10Day": 159440,
    "regularMarketPreviousClose": 332.67,
    "fiftyDayAverage": 311.409,
    "trailingAnnualDividendRate": null,
    "open": 326.36,
    "averageVolume10days": 159440,
    "expireDate": null,
    "algorithm": null,
    "dividendRate": null,
    "exDividendDate": null,
    "circulatingSupply": null,
    "startDate": null,
    "regularMarketDayLow": 312.49,
    "currency": "USD",
    "regularMarketVolume": 388695,
    "lastMarket": null,
    "maxSupply": null,
    "openInterest": null,
    "marketCap": 16292262912,
    "volumeAllCurrencies": null,
    "strikePrice": null,
    "averageVolume": 201561,
    "dayLow": 312.49,
    "ask": 322.29,
    "askSize": 1000,
    "volume": 388695,
    "fiftyTwoWeekHigh": 382.15,
    "fromCurrency": null,
    "fiveYearAvgDividendYield": null,
    "fiftyTwoWeekLow": 248.21,
    "bid": 311,
    "tradeable": false,
    "dividendYield": null,
    "bidSize": 900,
    "dayHigh": 328.71,
    "regularMarketPrice": 312.58,
    "preMarketPrice": null,
    "logo_url": "https://logo.clearbit.com/argenx.com"
}